|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2003-5-16
|
|
pubmed:abstractText |
4-benzylquinolines 5, based on a series of isoquinolines 1, were prepared and tested as inhibitors of the IGF/IGFBP-3 complex based on their ability to displace IGF-I from its binding to IGF-binding protein-3. SAR studies on the 6,7-dihydroxy moiety of the quinoline 5a showed that the catecol moiety could be replaced with other functional groups. Computational modeling of the 5a/mini-IGFBP-5 complex revealed the possible binding site of 5a on IGFBP-5.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:ConnorsPatrickP,
pubmed-author:GaoYinghongY,
pubmed-author:GrossRaymondR,
pubmed-author:GrossTimothyT,
pubmed-author:LingNicholasN,
pubmed-author:McCarthyJames RJR,
pubmed-author:StrackNathalieN,
pubmed-author:WangXiao-ChuanXC,
pubmed-author:WilcoxenKeithK,
pubmed-author:XXX,
pubmed-author:YewP RPR,
pubmed-author:ZhuYun-FeiYF
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
2
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1931-4
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12749901-Acids, Carbocyclic,
pubmed-meshheading:12749901-Amino Acid Sequence,
pubmed-meshheading:12749901-Binding, Competitive,
pubmed-meshheading:12749901-Binding Sites,
pubmed-meshheading:12749901-Humans,
pubmed-meshheading:12749901-Insulin-Like Growth Factor Binding Protein 3,
pubmed-meshheading:12749901-Insulin-Like Growth Factor Binding Protein 5,
pubmed-meshheading:12749901-Insulin-Like Growth Factor I,
pubmed-meshheading:12749901-Models, Molecular,
pubmed-meshheading:12749901-Molecular Sequence Data,
pubmed-meshheading:12749901-Quinolines,
pubmed-meshheading:12749901-Structure-Activity Relationship
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Quinoline-carboxylic acids are potent inhibitors that inhibit the binding of insulin-like growth factor (IGF) to IGF-binding proteins.
|
|
pubmed:affiliation |
Neurocrine Biosciences, Inc., 10555 Science Center Drive, San Diego, CA 92121, USA.
|
|
pubmed:publicationType |
Journal Article
|
